سعر سيمولكت 20مجم باودر فيال للتسريب الوريدي 2026

Simulect (basiliximab) 20 mg lyophilized powder vial for intravenous injection/infusion (Novartis); a chimeric monoclonal antibody that blocks the interleukin-2 receptor alpha chain (CD25), used to prevent acute rejection after kidney transplantation.

• Prophylaxis of acute organ rejection in renal transplantation, with cyclosporine (modified) and corticosteroids.Population: Adult and pediatric renal transplant recipientsDailyMed (U.S. National Library of Medicine)

• In controlled renal transplant trials the adverse event profile was similar to placebo; the most frequently reported events were gastrointestinal disorders (69% vs 67% placebo).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to basiliximab or any other component of the formulation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• BOXED WARNING: only physicians experienced in immunosuppression therapy and management of organ transplant patients should prescribe; patients should be managed in facilities with adequate laboratory and supportive resources.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe acute hypersensitivity reactions including anaphylaxis (within 24 hours) on first exposure or re-exposure; use extreme caution with a subsequent course, especially if concomitant immunosuppression was stopped prematurely after the first course.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Patients on immunosuppressive therapy are at increased risk of lymphoproliferative disorders and opportunistic infections and should be monitored.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Azathioprine, mycophenolate mofetil (with cyclosporine and corticosteroids)Basiliximab clearance was reduced by an average 22% (azathioprine) and 51% (mycophenolate mofetil); no dose adjustment necessary.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; IgG crosses the placenta and the IL-2 receptor may be important in immune development. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus; women of childbearing potential should use effective contraception before, during and for 4 months after completion of therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk; decide whether to discontinue nursing or the drug, considering the importance of the drug to the mother.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Basiliximab: Binds with high affinity to the alpha chain (IL-2Rα) of the high-affinity IL-2 receptor on activated T lymphocytes, competitively inhibiting IL-2-mediated lymphocyte activation.